share_log

HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $69

HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $69

HC Wainwright & Co. 維持對rhythm pharmaceuticals的買入評級,將目標價提高至69美元
Benzinga ·  11/07 21:13  · 評級/大行評級

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $64 to $69.

HC Wainwright & Co.分析師Raghuram Selvaraju維持對rhythm pharmaceuticals(納斯達克:RYTM)的買入評級,並將目標股價從64美元上調至69美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論